Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells

Cancer Research

Volumn 66, Issue 23, 2006, Pages 11447-11454

  Kausche, Sandra ^a   Wehler, Thomas ^a   Schnürer, Elke ^a   Lennerz, Volker ^a   Brenner, Walburgis ^a   Melchior, Sebastian ^a   Gröne, Mark ^a   Nonn, Marion ^a   Strand, Susanne ^a   Meyer, Ralf ^a   Ranieri, Elena ^b   Huber, Christoph ^a   Falk, Christine S ^c   Herr, Wolfgang ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF BARI   (Italy)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; LEUKOCYTE ANTIGEN;

ALLOIMMUNIZATION; ARTICLE; CANCER CELL; CANCER INFILTRATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CROSS REACTION; CYTOLYSIS; DONOR; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; MIXED LYMPHOCYTE CULTURE; NATURAL KILLER CELL; PRIORITY JOURNAL; SIBLING;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD3; ANTIGENS, CD8; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; KIDNEY NEOPLASMS; L-SELECTIN; LYMPHOCYTES, TUMOR-INFILTRATING; SIBLINGS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 33845778886     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0998     Document Type: Article

References (49)

1. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human Interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunothérapie. N Engl J Med 1998;338:1272-8.
2. Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 1988;48;206-14.
3. 8+ tumorinfiltrating lymphocytes in human renal cell carcinoma. Cancer Res 1990;50:2363-70.
4. Schleypen JS, Von Geldern M, Weiss EH, et al. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class 1 allotypes. Int J Cancer 2003;106:905-12.
5. Schendel DJ, Gansbacher B, Oberneder R, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993;151:4209-20.
6. Gaugler B, Brouwenstijn N, Vantomme V et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 1996;44:323-30.
7. Brandle D, Brasseur F, Weynants P, Boon T, Van den EB. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 1996;183:2501-8.
8. Gaudin C, Kremer F, Angevin E, Scott V Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 1999;162:1730-8.
9. Probst-Kepper M, Stroobant V, Kridel R, et al. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. J Exp Med 2001;193:1189-98.
10. Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 2004:427:252-6.
11. Brossart P, Stuhler G, Flad T, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998;58:732-6.
12. Vissers JL, De Vries IJ, Schreurs MW, et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999;59:5554-9.
13. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001;193:73-88.
14. + T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003;63:4481-9.
15. Tatsumi T, Kierstead LS, Ranieri E, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002;196:619-28.
16. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
17. Childs R, Bradstock K, Gottlieb D, et al. Non-myeloablative allogeneic stem cell transplantation (NST) for metastatic melanoma: nondurable chemotherapy responses without clinically meaningful graft-vs-tumor (GVT) effects. Blood 2002;100:429a.
18. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-8.
19. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002;20:2017-24.
20. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002;99:4234-6.
21. + IFN-γ-producing T cells. Bone Marrow Transplant 2004;33:491-7.
22. Tykodi SS, Warren EH, Thompson JA, et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004;10:7799-811.
23. + cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expressioa Blood 2004;104:2591-9.
24. Gunawan B, Huber W, Holtrup M, et al. Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res 2001;61:7731-8.
25. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-63.
26. Wolfel T, Hauer M, Klehmann E, et al. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int J Cancer 1993;55:237-44.
27. Herr W, Wolfei T, Heike M, Meyer zum Buschenfelde KH, Knuth A. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunol Immunother 1994;39:93-9.
28. Coulie PG, Ikeda H, Baurain JF, Chiari R. Antitumor immunity at work in a melanoma patient. Adv Cancer Res 1999;76:213-42.
29. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 2004;92:13-27.
30. Biswas K, Richmond A, Rayman P, et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunctioa Cancer Res 2006;66:6816-25.
31. Zou W. Regulatory T cells, tumour immunity, and immunotherapy. Nat Rev Immunol 2006;6:295-307.
32. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6.
33. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004;20:107-18.
34. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
35. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
36. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
37. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-84.
38. Nash RA, Storb R Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL. Curr Opin Immunol 1996;8:674-80.
39. Porter DL, Connors JM, Van Deerlin VM, et al. Graftversus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 1999;17:1234-43.
40. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99:3916-22.
41. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-55.
42. Wehler TC, Nonn M, Brandt B, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from anti-leukemic and anti-tumor donor T-cell lines. Blood. Epub 2006 Aug 24.
43. Schendel DJ, Falk CS, Nossner E, et al. Gene transfer of human Interferon γ complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity. Gene Ther 2000;7:950-9.
44. Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ. Mature dendritic cells pulsed with freezethaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000;96:1857-64.
45. Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer 2001;91:749-56.
46. Montagna D, Schiavo R, GibeUi N, et al. Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identicaf sibling. Int J Cancer 2004;110:76-86.
47. + T cells. Immunol Rev 2002;186:221-33.
48. + T cells. J Clin Invest 2005;115:1616-26.
49. Lennerz V, Fatho M, Gentilini C, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005;102:16013-8.